Sydney Translational Imaging Laboratory, Heart Research Institute & Charles Perkins Centre, Sydney Medical School, University of Sydney, NSW 2006, Australia.
Sydney Translational Imaging Laboratory, Heart Research Institute & Charles Perkins Centre, Sydney Medical School, University of Sydney, NSW 2006, Australia; School of Medicine, University of Notre Dame, Sydney, Australia.
Neuroimage Clin. 2019;21:101668. doi: 10.1016/j.nicl.2019.101668. Epub 2019 Jan 8.
Major depressive disorder (MDD) is a chronic disease with a large global impact. There are currently no clinically useful predictors of treatment outcome, and the development of biomarkers to inform clinical treatment decisions is highly desirable.
In this exploratory study we performed fixel-based analysis of diffusion MRI data from the International Study to Predict Optimized Treatment in Depression with the aim of identifying novel biomarkers at baseline that may relate to diagnosis and outcome to treatment with antidepressant medications. Analyses used MR data from individuals with MDD (n = 221) and healthy controls (n = 67).
We show focal, gender-specific differences in the anterior limb of the internal capsule (males) and bilaterally in the genu of the corpus callosum (females) associated with diagnosis. Lower fibre cross-section in the tapetum, the conduit between the right and left hippocampi, were also associated with a decreased probability of remission. Analysis of conventional fractional anisotropy showed scattered abnormalities in the corona radiata, cerebral peduncles and mid-brain which were much lower in total volume compared to fixel-based analysis.
Fixel-based analysis appeared to identify different underlying abnormalities than conventional tensor-based metrics, with almost no overlap between significant regions. We show that MDD is associated with gender specific abnormalities in the genu of the corpus callosum (females) and in the anterior limb of the internal capsule (males), as well as gender-independent differences in the tapetum that predict remission. Diffusion MRI may play a key role in future guidance of clinical decision-making for MDD.
重度抑郁症(MDD)是一种具有全球重大影响的慢性疾病。目前,尚无治疗结果的临床有用预测指标,开发用于告知临床治疗决策的生物标志物是非常需要的。
在这项探索性研究中,我们对来自国际预测抑郁症优化治疗研究的弥散磁共振成像数据进行了固定点分析,目的是确定基线时可能与抗抑郁药物治疗的诊断和结果相关的新的生物标志物。分析使用了 MDD 患者(n=221)和健康对照者(n=67)的 MR 数据。
我们显示,与诊断相关的是,内囊前肢(男性)和胼胝体膝部(女性)存在局灶性、性别特异性差异。内连左右海马的穹窿体纤维横截面积较小与缓解的可能性降低有关。传统各向异性分数的分析显示,放射冠、大脑脚和中脑存在散在的异常,与固定点分析相比,这些异常的总体积要低得多。
与传统张量基度量相比,固定点分析似乎可以识别出不同的潜在异常,而显著区域之间几乎没有重叠。我们表明,MDD 与胼胝体膝部(女性)和内囊前肢(男性)的性别特异性异常有关,以及与缓解相关的穹窿体的性别独立差异。弥散磁共振成像可能在未来的 MDD 临床决策指导中发挥关键作用。